中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2014年
8期
1-4
,共4页
康健%吴大鹏%刘强%沈海波%顾正勤%梁军号%齐隽
康健%吳大鵬%劉彊%瀋海波%顧正勤%樑軍號%齊雋
강건%오대붕%류강%침해파%고정근%량군호%제준
前列腺肿瘤%复发%内分泌治疗%Gleason评分
前列腺腫瘤%複髮%內分泌治療%Gleason評分
전렬선종류%복발%내분비치료%Gleason평분
Prostatic neoplasms%Recurrence%Endocrine therapy%Gleason score
目的 评估影响前列腺癌患者内分泌治疗有效时间的临床相关因素.方法 回顾性分析432例诊断为前列腺癌并接受单纯内分泌治疗患者的临床资料.研究终点定义为内分泌治疗失效,即前列腺特异抗原(PSA)从最低值连续2次增加,并超过0.2μg/L.纳入分析的变量包括年龄、临床分期、淋巴转移情况、骨转移情况、Gleason评分、初始PSA水平以及PSA最低值,通过Cox回归模型检测其与内分泌治疗有效时间的相关关系.结果 432例患者发病年龄57 ~88 (73.70±7.28)岁.初始PSA水平10.30~588.10(27.15±75.90)μg/L.内分泌治疗有效时间3~62(27.01±13.10)个月.单因素分析表明,初始PSA水平、临床分期、Gleason评分、PSA最低值、淋巴结转移和骨转移与内分泌治疗有效时间存在显著相关关系(P<0.01).多因素分析中,仅Gleason评分与内分泌治疗有效时间存在显著相关关系(P=0.001).与Ghason评分≤3+4分相比,≥4+3分患者的内分泌治疗失效风险增加2.49倍,95% CI 1.44~4.30.结论 在不同分期的前列腺癌患者中,Gleason评分与内分泌治疗有效时间具有显著的相关性,Gleason评分≥4+3分患者显示出更短的内分泌治疗有效时间.
目的 評估影響前列腺癌患者內分泌治療有效時間的臨床相關因素.方法 迴顧性分析432例診斷為前列腺癌併接受單純內分泌治療患者的臨床資料.研究終點定義為內分泌治療失效,即前列腺特異抗原(PSA)從最低值連續2次增加,併超過0.2μg/L.納入分析的變量包括年齡、臨床分期、淋巴轉移情況、骨轉移情況、Gleason評分、初始PSA水平以及PSA最低值,通過Cox迴歸模型檢測其與內分泌治療有效時間的相關關繫.結果 432例患者髮病年齡57 ~88 (73.70±7.28)歲.初始PSA水平10.30~588.10(27.15±75.90)μg/L.內分泌治療有效時間3~62(27.01±13.10)箇月.單因素分析錶明,初始PSA水平、臨床分期、Gleason評分、PSA最低值、淋巴結轉移和骨轉移與內分泌治療有效時間存在顯著相關關繫(P<0.01).多因素分析中,僅Gleason評分與內分泌治療有效時間存在顯著相關關繫(P=0.001).與Ghason評分≤3+4分相比,≥4+3分患者的內分泌治療失效風險增加2.49倍,95% CI 1.44~4.30.結論 在不同分期的前列腺癌患者中,Gleason評分與內分泌治療有效時間具有顯著的相關性,Gleason評分≥4+3分患者顯示齣更短的內分泌治療有效時間.
목적 평고영향전렬선암환자내분비치료유효시간적림상상관인소.방법 회고성분석432례진단위전렬선암병접수단순내분비치료환자적림상자료.연구종점정의위내분비치료실효,즉전렬선특이항원(PSA)종최저치련속2차증가,병초과0.2μg/L.납입분석적변량포괄년령、림상분기、림파전이정황、골전이정황、Gleason평분、초시PSA수평이급PSA최저치,통과Cox회귀모형검측기여내분비치료유효시간적상관관계.결과 432례환자발병년령57 ~88 (73.70±7.28)세.초시PSA수평10.30~588.10(27.15±75.90)μg/L.내분비치료유효시간3~62(27.01±13.10)개월.단인소분석표명,초시PSA수평、림상분기、Gleason평분、PSA최저치、림파결전이화골전이여내분비치료유효시간존재현저상관관계(P<0.01).다인소분석중,부Gleason평분여내분비치료유효시간존재현저상관관계(P=0.001).여Ghason평분≤3+4분상비,≥4+3분환자적내분비치료실효풍험증가2.49배,95% CI 1.44~4.30.결론 재불동분기적전렬선암환자중,Gleason평분여내분비치료유효시간구유현저적상관성,Gleason평분≥4+3분환자현시출경단적내분비치료유효시간.
Objective To assess the clinical factors impacting on the effective time of endocrine therapy for patients with prostate cancer.Methods The chnical data of 432 patients with prostate cancer who accepted endocrine therapy were analyzed retrospectively.The endpoint of the study was failure of endocrine therapy which was defined as continuous elevation of prostate specific antigen (PSA) from nadir for 2 times and more than 0.2 μg/L.The clinical data such as age,clinical stage,lymph node metastasis,bone metastasis,Gleason score,initial PSA,and PSA nadir were collected and their rehtionship with the effective time of endocrine therapy were further assessed via COX regression model.Results Age of onset was 57-88(73.70 ± 7.28) years.Initial PSA was 10.30-588.10(27.15 ± 75.90) μ g/L.The effective time of endocrine therapy was 3-62 (27.01 ± 13.10) months.Univariate regression analysis showed that initial PSA,clinical stage,Gleason score,PSA nadir,lymph node metastasis,bone metastasis were correlated with the effective time of endocrine therapy (P < 0.01).Multivariate regression analysis showed that only Gleason score was correlated with the effective time of endocrine therapy(P=0.001).Compared with patients with Gleason score equal to or less than 3+4,patients with Gleason score equal to or more than 4+3 showed 2.49 fold increased risk of therapy failure (OR =2.49,95% CI 1.44-4.30).Conclusion Gleason score has close relationship with the effective time of endocrine therapy for patients with prostate cancer,Gleason score equal to or more than 4+3 is an indicator for poor response to endocrine therapy.